【医保动态】培美替尼在中国纳入国家医保目录了吗？

Pemetinib is a selective fibroblast growth factor receptor (FGFR) kinase inhibitor that blocks the growth and spread of tumor cells by blocking FGFR2 in tumor cells. Pemetinib has previously been granted orphan drug status, breakthrough drug status, and priority review status by the U.S. FDA. It was also granted Orphan Drug Designation (ODD) by Japan's MHLW. Incyte announced on March 23, 2021 that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved pemigatinib for the treatment of patients with unresectable cholangiocarcinoma (BTC) who carry the FGFR2 fusion gene and whose condition has worsened after receiving anti-cancer chemotherapy.

Pemetinib exhibits antitumor activity in mouse xenograft models of human tumors harboring FGFR1, FGFR2, or FGFR3 alterations, resulting in constitutive FGFR activation, including cholangiocarcinoma xenograft models in patients expressing oncogenic FGFR2-Transformer-2 beta homolog (TRA2b) fusion proteins.

Has pemetinib been included in the national medical insurance directory in China? Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.